U.S. GOVERNMENT, ASTRAZENECA SIGN A $486 MILLION COVID-19 ANTIBODY AGREEMENT

Highlights

• U.S. to fund AstraZeneca for the late-stage development and large-scale manufacture of AZD7442, a fusion of two monoclonal antibodies, for the potential treatment or prevention of COVID-19

• AstraZeneca will utilize these funds for two Phase III trials and development and manufacturing for the supply of AZD7442 doses in the country of America

• The UK-based pharmaceutical company has ap....